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doi:10.1Objective: One of the most significant responses to fetal cardiac bypass is severe placental dysfunction charac-
terized by increased vascular resistance. We tested the hypothesis that fetal cardiac bypass triggers the activation
of nuclear factor kappa-B (NF-KB), a major regulator of inflammatory response, and that pharmacologic inhi-
bition of NF-KB activation by pyrrolidine dithiocarbamate alleviates fetal cardiac bypass–induced placental
dysfunction.
Methods: Fifteen pregnant goats at 120 to 140 days’ gestation were equally divided into the control group with
a sham procedure of fetal sternotomy and cannulation (CG), the fetal bypass group (FB), and the fetal bypass
group with 300 mg pyrrolidine dithiocarbamate before sternotomy (FP). Fetal cardiac bypass was performed
for 30 minutes. Umbilical arterial flow rate was measured by ultrasonic flowmeter and placental vascular resis-
tance was calculated. Fetal plasma levels of nitric oxide (NO), endothlin-1 (ET-1), 6-keto-prostaglandin F1a
(6-K), thromboxane B2 (TXB2), interleukin 6 (IL-6), and tumor necrosis factor-a (TNF-a) were assayed.
IL-6 and TNF-amRNAwere analyzed by real-time polymerase chain reaction. NF-KB activation was evaluated
by electrophoretic mobility shift assay.
Results: Placental vascular resistance significantly increased in the FB and FP groups compared with the CG
group. Increases in plasma levels of NO were observed in all 3 groups. Plasma levels of ET-1 rose significantly
in the FB and FP groups without noticeable difference between them. Plasma levels of 6-K, TXB2, IL-6, and
TNF-a increased significantly in the FB group compared with the CG and FP groups. The transcription levels
of IL-6 and TNF-a mRNA in the placental tissues of the FB group were significantly higher than in the FP and
CG groups. The amount of activated NF-KB in the placental tissues of the FB group was also significantly higher
than that in the FP and CG groups.
Conclusions: Fetal cardiac bypass–induced inflammatory response possibly mediated by NF-KB caused pla-
cental dysfunction. Pharmacologic inhibition of NF-KB activation and decrease in the inflammatory response
did not alleviate the placental dysfunction. (J Thorac Cardiovasc Surg 2012;143:445-50)E
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SIt is believed that in utero correction of certain congenital
heart defects may benefit the growth and development of
the heart, preventing secondary changes from abnormal
blood flow patterns. Fetal cardiac surgical intervention of-
ten requires extracorporeal circulation support with unde-
sirable side effects. The most significant response to fetal
extracorporeal circulation is severe placental dysfunction
characterized by increased vascular resistance, reduced
blood flow, and subsequent impairment of fetal gase Department of Cardiovascular Surgery, Guangdong Provincial Cardiovas-
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The Journal of Thoracic and Caexchange. The pathophysiology of postbypass placental
dysfunction includes release of prostanoids, endothelial
dysfunction, leukocyte and complement activation, and
other inflammatory pathways.1-6
Umbilical vessels are not innervated and therefore vaso-
dilatation must occur through direct vasorelaxant paracrine
effect of agents acting on placental vessels in their physio-
logic state. Several agents modulate the tone of the cord and
villous vessels of the placenta, such as vasodilatation agents
prostacyclin, nitric oxide (NO), atrial natriuretic peptide
and vasoconstriction agents thromboxane A2 (TXA2),
endothelin-1 (ET-1), and angiotensin.7-10 Most of these
are proinflammatory mediators.
Nuclear factor kappa-B (NF-KB) is a major transcription
factor involved in the regulation of inflammatory response.
Under physiologic conditions, NF-KB combines with in-
hibitor kappa-B and is stored in the cytoplasm. On activa-
tion, NF-KB translocates to the nucleus and binds the
sequence GGGRNNYYCC on target gene promoters, initi-
ating transcription of genes for cyclooxygenase, nitric oxide
synthase (NOS), ET-1, angiotensin, and some inflammatory
mediators, such as interleukin (IL) 6 and tumor necrosisrdiovascular Surgery c Volume 143, Number 2 445
Abbreviations and Acronyms
CG ¼ control group
EMSA ¼ electrophoretic mobility shift assay
ET-1 ¼ endothelin-1
FB ¼ fetal cardiac bypass group
FP ¼ fetal cardiac bypass with pyrrolidine
dithiocarbamate group
IL ¼ interleukin
6-K ¼ 6-keto-prostaglandin F1a
NF-KB ¼ nuclear factor kappa-B
NO ¼ nitric oxide
NOS ¼ nitric oxide synthase
PDTC ¼ pyrrolidine dithiocarbamate
TNF-a ¼ tumor necrosis factor-a
TXA2 ¼ thromboxane A2
TXB2 ¼ thromboxane B2
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opment and labor.11-14 We hypothesize that fetal cardiac
bypass activates NF-KB, causing an inflammatory mediator
burst that constricts placental vessels and that pharmaco-
logic inhibition of NF-KBmight alleviate the placental dys-
function induced by fetal cardiac bypass. We used fetal goat
cardiac bypass as an animal model to test our hypothesis.
MATERIALS AND METHODS
The study protocol was approved by the Animal Research Committee of
GuangdongGeneral Hospital. All animals were handled in accordancewith
the Guidelines of the Guangdong General Hospital for Laboratory Animal
Studies.
Animal Model
Fifteen pregnant goats with gestational age between 120 and 140 days
were randomly and equally divided into a control group (CG), a fetal by-
pass group (FB), and a fetal bypass with pyrrolidine dithiocarbamate
(PDTC) group (FP). PDTC, a specific antagonist of NF-KB, was given in-
travenously in a dose of 300 mg after fetal sternotomy to each animal in the
FP group. Surgical preparation and fetal cardiac bypass techniquewere car-
ried out as previously described.15 The CG group underwent fetal sternot-
omy and cannulation without fetal cardiac bypass. The other groups
underwent fetal cardiac bypass for 30 minutes. Hemodynamic data points
of the maternal and fetal goats were continuously recorded using a model
64S monitor (Hewlett-Packard Company, Palo Alto, Calif).
Fetal Cardiac Bypass
As previously described,15 a fetal median sternotomy was performed
and the pericardiumwas opened. Fetal cardiac bypass was achieved by can-
nulation of themain pulmonary artery using an 8FDLP arterial cannula and
the right atrium with a 12F angled-tipped venous cannula (Medtronic, Inc,
Minneapolis, Minn). A normothermic and nonpulsatile pump system, con-
sisting of a centrifugal pump (Medtronic, BP50), the placenta, and a mini-
mal heat exchanger (Derun Medical Instrument Co, Guangdong, China)
was primed with 150 mL adult goat blood and 50 mL lactated Ringer so-
lution containing 10 mg heparin. No steroid was used in the pump prime.
The flow rate was maintained at least 250 mL $ kg1 $min1 for 30 minutes
in both groups FB and FP before bypass was terminated, and all the animals446 The Journal of Thoracic and Cardiovascular Surgwere monitored for 2 hours before they were humanely killed for autopsy
and measurement of fetal weight.
Placental Vascular Resistance
Umbilical mean arterial pressure and flow rate were measured using
a 22-gauge indwelling catheter in the lumen of an umbilical artery and
an ultrasound blood flowmeter (Transonic Systems, Inc, Ithaca, NY) in
the same artery. Placental vascular resistance was calculated as the ratio
of umbilical mean arterial pressure over flow rate.
Blood Sample Regimen
Fetal blood samples from the umbilical vein were collected for blood
gas analysis with a GEMPremier 3000 blood gas analyzer (Instrumentation
Laboratory, Bedford, Mass) immediately before cardiac bypass (T0), at 30
minutes into and immediately before termination of cardiac bypass (T1),
and 1 and 2 hours after bypass (T2 and T3). All the fetal blood samples
for inflammatory mediator assays were collected in a similar fashion and
time points and placed immediately in test tubes containing ethylenediami-
netetraacetic acid on ice, centrifuged at 3000 rpm for 15minutes in a cooled
centrifuge, and the supernatants were then frozen at70C.
Assay of Inflammatory Mediator
Plasma NO level was measured by a chemical fluorescence technique
(Nanjing Juli Biological Technical Co, Nanjing, China). Radioimmuno-
assays (Beijing Ke Mei Dong Ya Biological Technical Co, Beijing,
China) were used to assay fetal plasma levels of ET-1 as well as
6-keto-prostaglandin F1a (6-K) and thromboxane B2 (TXB2), metabolic
substrates of prostacyclin and TXA2. Fetal plasma levels of IL-6 and
TNF-a were assayed by enzyme-linked immunosorbent assay (Guang-
zhou Weijia Biological Technical Co, Guangzhou, China).
Tissue Collection
Placental samples of approximately 200 mg from the fetal side were
harvested after sternotomy at time point T0 and at other corresponding
time points T1, T2, and T3. Samples were immediately frozen in liquid
nitrogen.
Real-Time Polymer Chain Reaction Analysis
Total RNAwas extracted from fetal placental tissues collected at T0 and
T3 with Trizol reagent (Invitrogen, Carlsbad, Calif) and the concentrations
were spectrophotometrically determined. Real-time quantitative reverse
transcriptase polymer chain reaction analysis was performed with an
ABI 7700 Sequence Detection System using TaqMan chemistry (Applied
Biosystems, San Jose, Calif). Primers for IL-6 were 50-GCTGCTCC
TGGTGATGACTTC-30 and 50-GGTGGTGTCATTTTTGAAATCTTCT -30.
The amplicon was detected using the bifunctional fluorogenic probe
50-FAM-CTTTCCCTACCCCGGGTCCC- TAMRA-30. Primers for TNF-a
were 50-TTCAACAGGCCTCTGGTTCAG-30 and 50-TGGGCTACCGGC
TTGTTACT-30, and fluorogenic probe was 50-FAM-CACTCAGGTCATC
TTCTCAAGCCTC-TAMRA-30. All reactions were performed in duplicate.
Final results are absolute copy number per 1 mg total RNA.
Electrophoretic Mobility Shift Assay (EMSA)
NF-KB binding was determined by EMSA. Nuclear protein from all the
fetal placental tissue samples were extracted with NE-PER nuclear and cy-
toplasmic extraction reagents (Pierce Protein Research Products, division
of Thermo Fisher Scientific, Rockford, Ill) according to the manufacturer’s
instructions. The probe oligonucleotide was 22-bp, double-stranded
(50-GCCTGGGAAAGTCCCCTCAACT-30), and end-labeled with biotin
(Yinjun Biological Technical Co, Shanghai, China). DNA-binding reac-
tions were loaded into a 6% polyacrylamide gel, separated at 100 V for
30 minutes, and transferred at 100 V for 30 minutes to a positively chargedery c February 2012
Zhou et al Evolving Technology/Basic Sciencenylon membrane. Transferred DNA was immediately cross-linked to the
membrane on an ultraviolet transilluminator equipped with 312-nm bulbs
and detected using horseradish peroxidase–conjugated streptavidin (Light-
Shift Chemiluminescent EMSA kit) according to the manufacturer’s
instructions.
Statistical Analysis
IL-6 and TNF-amRNA levels in each group were compared by the Stu-
dent t test. Intergroup comparisons were performed by repeated-measures
analysis of variance. Intragroup comparisons were performed by 1-way
analysis of variance. Statistical analysis was performed with the SPSS
13.0 software package (SPSS, Inc, Chicago, Ill). The data were expressed
as means  standard deviation.RESULTS
Fetal Hemodynamics, Placental Vascular Resistance,
and Placental Gas Exchange
The mean bypass flow rates in the FB group (290  32
mL $ kg1 $ min1) and FP group (289  32 mL $ kg1 $
min1) were not significantly different. The mean dosage
of PDTC in the FP group was 175  25 mg/kg. As shown
in Table 1, no significant difference in mean arterial pres-
sure was detected among the 3 groups during theTABLE 1. Fetal hemodynamics, placental vascular resistance, and placen
Group T0 T1
MAP (mm Hg)
CG 51.6  11.0 47.4 
FB 55.6  9.8 58.0 
FP 58.6  5.8 63.8 
HR (beats/min)
CG 188  28 173 
FB 202  25 142 
FP 195  32 152 
PVR (mm Hg $ mL1 $ kg1 $ min1)
CG 0.25  0.06 0.28 
FB 0.35  0.08 0.64 
FP 0.33  0.06 0.64 
pH
CG 7.31  0.06 7.35 
FB 7.35  0.08 7.27 
FP 7.35  0.06 7.36 
PCO2 (mm Hg)
CG 40.6  2.2 42.0 
FB 38.2  7.2 46.8 
FP 39.6  5.5 44.8 
PO2 (mm Hg)
CG 28.8  3.0 30.0 
FB 29.4  4.6 26.0 
FP 27.8  6.4 28.8 
Base excess (mmol/L)
CG 3.8  2.6 3.4 
FB 3.4  4.4 7.4 
FP 5.4  3.5 6.8 
T0, Immediately before cardiac bypass; T1, at 30minutes into and immediately before termi
arterial blood pressure; HR, heart rate; PVR, placental vascular resistance; Pco2, partial p
bypass group; FP, fetal cardiac bypass with pyrrolidine dithiocarbamate group. *P<.05 c
The Journal of Thoracic and Caexperiments. The heart rate was higher before bypass and
returned to fetal physiologic level during and after bypass
in the FP group. Overall, heart rates were not significantly
different among the 3 groups.
Placental vascular resistance and blood gas values re-
mained within normal physiologic range in the CG group.
Placental vascular resistance increased markedly in the
FB and FP groups at T3 (Table 1). The partial pressure of
carbon dioxide increased significantly, accompanied by a re-
markable decline in pH and base excess values in the FB
and FP groups. However, no significant difference was de-
tected in oxygen tension among the 3 groups.
Inflammatory Mediators
As shown in Figure 1, the plasma levels of NO gradually
increased in all 3 groups, and differences among the groups
were significant (P ¼ .016). The plasma level of NO in the
FB group was higher than that in the CG group; however, no
difference was observed between either the FB and FP
groups or the FP and CG groups. The difference among
the 3 groups in the plasma level of ET-1 was remarked
(P = .048). Although the plasma ET-1 did not show anytal gas exchange
T2 T3 P value
9.0 46.6  13.4 46.2  11.4 .867
7.8 51.0  1.4 47.0  6.6 .111
11.9 56.4  7.1 52.2  6.3 .195
39 177  29 173  25 .829
20 154  22 150  66 .096
19* 175  12 159  10* .019
0.05 0.28  0.08 0.29  0.04 .663
0.22 0.82  0.47 1.31  0.59* .010
0.36 0.60  0.23 0.98  0.36* .020
0.05 7.31  0.06 7.32  0.03 .429
0.06 7.24  0.05 7.04  0.14* .010
0.05 7.22  0.04 7.13  0.08* .000
5.3 41.8  6.2 43.6  3.8 .788
5.9 50.0  11.2* 64.8  9.5* .010
5.0 49.8  1.9* 60.4  4.8* .000
4.4 29.2  3.1 28.0  1.6 .784
4.2 25.8  4.9 26.4  5.3 .607
2.6 29.8  6.1 21.4  6.4 .119
2.4 2.9  2.0 4.1  3.2 .906
4.7 5.2  5.2 14.2  2.9* .007
3.1 4.8  3.0 11.9  1.6* .006
nation of cardiac bypass; T2, 1 hour after bypass; T3, 2 hours after bypass;MAP,Mean
ressure of carbon dioxide; Po2, oxygen tension; CG, control group; FB, fetal cardiac
ompares in-group versus T0.
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FIGURE 1. Fetal plasma inflammatory mediators: A, Changes in fetal plasma nitric oxide (NO). B, Changes in fetal plasma endothelin-1 (ET-1).
C, Changes in fetal plasma 6-keto-prostaglandin F1a (6-K). D, Changes in fetal plasma thromboxane B2 (TXB2). E, Changes in fetal plasma interleukin
6 (IL-6). F, Changes in fetal plasma tumor necrosis factor-a (TNF). *P<.05 comparison within groups versus T0. CG, Control group; FB, fetal bypass
group; FP, pyrrolidine dithiocarbamate group; T0, immediately before cardiac bypass; T1, at 30 minutes into and immediately before termination of cardiac
bypass; T2, 1 hour after bypass; T3, 2 hours after bypass.
TABLE 2. Levels of IL-6 and TNF-a mRNA
Group T0 T3 P value
IL-6 mRNA (106 copies/mg
total RNA)
CG 1.10  0.55 1.40  0.48 .270
FB 1.71  0.65 3.24  1.38 .027
FP 1.10  0.57 1.55  0.95 .235
TNF-a mRNA (106 copies/mg
total RNA)
CG 0.59  0.29 0.76  0.37 .261
FB 0.90  0.40 2.18  0.94 .044
FP 0.73  0.29 0.81  0.58 .714
T0, Immediately before cardiac bypass; T3, 2 hours after bypass; IL-6, interleukin 6;
TNF-a, tumor necrosis factor-a; mRNA, messenger RNA; CG, control group; FB,
fetal cardiac bypass group; FP, fetal cardiac bypass with pyrrolidine dithiocarbamate
group.
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evations in the FB and FP groups at T3 without any signif-
icant difference between them. Significant differences in
plasma 6-K and TXB2 levels were seen among groups (6-
K, P ¼ .010; TXB2, P ¼ .015), although these clearly in-
creased for all 3 groups. Plasma levels of 6-K and TXB2
were the highest in the FB group, with no significant differ-
ence between the FP and CG groups. The difference among
the 3 groups in plasma IL-6 and TNF-a levels was marked
(IL-6, P¼ .012; TNF-a, P¼ .016), with higher levels in the
FB group compared with the FP and CG groups. No signif-
icant changes were seen between the FP and CG groups.
Likewise, levels of IL-6 and TNF-amRNA in the placental
tissue were markedly elevated at T3 in the FB group com-
pared with the CG and FP groups, but no significant differ-
ence was detected between the CG and FP groups (Table 2).
EMSA for NF-KB
Band shifts for the CG group showed no changes
throughout the experiment. Significant changes were seen
at T2 and T3 compared with T0 in the FB group. The
changes in the FP group were significant at T2 but not at
T3. EMSA results for T3 showed NF-KB was activated in
FB group, but not in the FP group (Figure 2).448 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Our study showed that several plasma inflammatory me-
diators with various vasoactive properties were released
after fetal cardiac bypass with subsequent placental vaso-
constriction and the accompanying fetal hypercarbia and
acidosis. The plasma levels of ET-1, a strong vasoconstric-
tive agent, increased significantly after fetal cardiac bypass
with subsequent increase in placental vascular resistance inery c February 2012
FIGURE 2. Electrophoreticmobility shift assay (EMSA) for nuclear factor
kappa-B (NF-KB) band shift for (A) groupCGat 4 time points, (B) groupFB
at 4 time points, and (C) group FP at 4 time points. CG, Control group; FB,
fetal bypass group; FP, pyrrolidine dithiocarbamate group; T0, immediately
before cardiac bypass; T1, at 30 minutes into and immediately before termi-
nation of cardiac bypass; T2, 1 hour after bypass; T3, 2 hours after bypass.
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was observed after manipulation in utero and did not seem
to have any effect on ET-1 at all. The plasma levels of 6-K
and TXB2, the metabolic substrates of prostacyclin and
TXA2, respectively, increased during and after fetal cardiac
bypass. Prostacyclin and TXA2 had contrary vasoactive
properties, but the combined effects on the placental vascu-
lar tone were vasoconstriction. The plasma levels of IL-6
and TNF-a, which were detrimental to placental functions
as previously reported,3 were also released significantly af-
ter fetal cardiac bypass in our study.
NF-KB is a major transcription factor involved in the reg-
ulation of inflammatory response, initiating transcription of
genes for cyclooxygenase, NOS, ET-1, and some inflamma-
tory mediators, such as TNF-a and IL-6. The EMSA results
in our study showed NF-KB in the placental tissues was per-
sistently activated after fetal cardiac bypass in the FB group.
The transcription levels of IL-6 and TNF-a mRNA in the
placental tissues were also markedly increased in the FB
group. These results and changes of inflammatory media-
tors suggested that NF-KB might be involved in the inflam-
matory response induced by fetal cardiac bypass.
PDTC is a relatively selective NF-KB inhibitor by
a mechanism that prevents degradation of inhibitor kappa-
B.16 We did not explore the dose–response relationship of
PDTC and instead opted to use 300 mg in the FP group
based on a previous study17 since the weights of the fetal
goats cannot be measured before the onset of the experi-
ments and the consideration that the bioavailability of
PDTC might be influenced by the placental exchange and
maternal metabolism. With the addition of PDTC to the
FP group, the amount of activated NF-KB was noticeably
reduced after fetal cardiac bypass compared with the FB
group. The polymer chain reaction assay revealed that theThe Journal of Thoracic and Catranscription levels of IL-6 and TNF-a mRNA in the pla-
cental tissues remained relatively unchanged in the FP
group but significantly increased in the FB group. We also
observed that other than NO and ET-1, all the inflammatory
mediators assayed (6-K, TXB2, IL-6, and TNF-a) were to
various extents suppressed in the FP group, and yet placen-
tal dysfunction with hypercarbia and acidosis were ob-
served in this group, not unlike the FB group, which did
not receive PDTC.
Reddy and colleagues4 reported that the basal endothelial
regulatory mechanisms of placental vascular tone were de-
ranged and ET-1 played the crucial roles in the placental
dysfunction after fetal cardiac bypass. PDTC suppressed
the activation of NF-KB but had no effects on ET-1 in our
study. It was reported that PDTC might reduce the expres-
sion of inducible NOS mRNA via the inhibition of activa-
tion of NF-KB.18 However, our study showed that PDTC
did not interfere with the release of NO in the placenta after
fetal cardiac bypass, and the coexisting high levels of NO
and ET-1 resulted in increased placental vascular tone after
fetal cardiac bypass, despite the fact that other inflamma-
tory mediators including 6-K, TXB2, IL-6, and TNF-a
were suppressed in the FP group. These results implicated
that ET-1 might be the inflammatory mediator primarily re-
sponsible for the increased placental vascular resistance and
dysfunction.
Recently, angiogenic imbalance is believed to lead to en-
dothelial dysfunction, systemic vasoconstriction, and
hypertension. Soluble fms-like tyrosine kinase 1 is an anti-
angiogenic factor against proangiogenic factor, such as vas-
cular endothelial growth factor in placenta.19 Murphy and
associates20 reported that ET-1 appears to play an important
role in mediating the hypertension produced by chronic, ex-
cess soluble fms-like tyrosine kinase 1 in normal pregnant
rats. Long-term treatment with an elective ET-1 receptor an-
tagonist significantly reduced mean arterial pressure in sol-
uble fms-like tyrosine kinase 1 hypertensive pregnant rats
while having no effect on normal pregnant rats. This inter-
action between ET-1 and soluble fms-like tyrosine kinase 1
might provide new direction for future investigation in the
field of fetal cardiac bypass and preservation of placental
function.
In summary, our data suggested that fetal cardiac bypass
activated NF-KB in placental tissue, promoted the placental
inflammatory response, and affected placental function.
However, pharmacologic inhibition of NF-KB with PDTC
did not improve placental function. ET-1, among all the in-
flammatory mediators we assayed, might play a primary
role in causing placental dysfunction.References
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